Asieris Receives Regulatory Approval for CEVIRA in China, Pioneering Non-Invasive Treatment for Cervical Lesions Asieris Pharmaceuticals celebrates the approval of CEVIRA, the first non-invasive therapy for cervical precancerous lesions in China, transforming treatment approaches.

Asieris Receives Regulatory Approval for CEVIRA in China, Pioneering Non-Invasive Treatment for Cervical Lesions #China #Nanjing #Asieris_Pharmaceuticals #Photocure_ASA #CEVIRA

Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings The BRAVO study reveals that while blue light cystoscopy incurs higher initial costs, lower recurrence rates lead to overall cost neutrality in bladder cancer care.

Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings #Norway #Oslo #Bladder_Cancer #Photocure_ASA #Blue_Light_Cystoscopy

The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025 The latest findings from the BRAVO study showcase the cost neutrality of blue light versus white light cystoscopy in treating bladder cancer, emphasizing real-world savings.

The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025 #Norway #Oslo #Bladder_Cancer #Photocure_ASA #BRAVO_Study

Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth Photocure ASA has announced strong financial results for Q3 2025, showcasing significant revenue growth and strategic partnerships aimed at enhancing bladder cancer detection.

Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook Photocure ASA highlights strong financial performance in Q3 2025, with increasing revenues and the advent of strategic partnerships for growth. Looking ahead, they anticipate sustained growth in bladder cancer diagnostics.

Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments Photocure ASA has announced a revenue increase for Hexvix®/Cysview® in Q1 2025. With strong performance in Europe and North America, growth looks promising for the year ahead.

Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments #Norway #Oslo #Bladder_Cancer #Photocure_ASA #Hexvix

AUA2025: Advances in Bladder Cancer Management with Blue Light Cystoscopy At AUA2025, Photocure ASA showcased Blue Light Cystoscopy's significant role in improving bladder cancer management and patient decision-making.

AUA2025: Advances in Bladder Cancer Management with Blue Light Cystoscopy #Las_Vegas #Norway #Bladder_Cancer #Photocure_ASA #Blue_Light_Cystoscopy

Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment At the EAU 2025 congress, Photocure ASA highlights significant advantages of Blue Light Cystoscopy in managing bladder cancer and reducing recurrence rates.

Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment #Photocure_ASA #Blue_Light_Cystoscopy #Hexvix

Photocure ASA Reports Strong Growth for Q4 2024 Results Photocure ASA shares impressive fourth quarter results with record revenues and product growth for Hexvix and Cysview, projecting continued success for 2025.

Photocure ASA Reports Strong Growth for Q4 2024 Results #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Robust Financial Performance in Q4 2024 Photocure ASA showcases impressive revenue growth in Q4 2024, driven by rising sales of Hexvix®/Cysview®. The company anticipates continued momentum through 2025.

Photocure ASA Reports Robust Financial Performance in Q4 2024 #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Enhancements in Bladder Cancer Management Using Blue Light Cystoscopy at ASCO GU 2025 Photocure ASA presented significant advancements in bladder cancer treatment through Blue Light Cystoscopy at ASCO GU 2025, focusing on patient outcomes.

Enhancements in Bladder Cancer Management Using Blue Light Cystoscopy at ASCO GU 2025 #USA #San_Francisco #Bladder_Cancer #Photocure_ASA #Blue_Light_Cystoscopy

Innovative Blue Light Cystoscopy Enhances Bladder Cancer Detection at ASCO GU 2025 Photocure ASA unveils groundbreaking findings on Blue Light Cystoscopy at ASCO GU 2025, highlighting its significance in bladder cancer management.

Innovative Blue Light Cystoscopy Enhances Bladder Cancer Detection at ASCO GU 2025 #Norway #Oslo #Photocure_ASA #Blue_Light_Cystoscopy #NMIBC